Publication

Long-term follow-up after treatment of common bile duct stones by extracorporeal shock-wave lithotripsy

Journal Paper/Review - Jun 1, 1996

Units
PubMed

Citation
Meyenberger C, Meierhofer U, Michel-Harder C, Knuchel J, Wirth H, Bühler H, Münch R, Altorfer J. Long-term follow-up after treatment of common bile duct stones by extracorporeal shock-wave lithotripsy. Endoscopy 1996; 28:411-7.
Type
Journal Paper/Review (English)
Journal
Endoscopy 1996; 28
Publication Date
Jun 1, 1996
Issn Print
0013-726X
Pages
411-7
Brief description/objective

BACKGROUND AND STUDY AIMS: The efficacy of extracorporeal shock-wave lithotripsy (ESWL) of difficult bile duct stones that were not amenable to routine endoscopic extraction was assessed, with evaluation of the long-term follow-up after successful treatment. PATIENTS AND METHODS: Fifty-four patients (mean age 74 years, range 33-92) were treated with ESWL for difficult bile duct stones. Treatment was performed either with the Dornier HM3 kidney lithotriptor (49 patients) or with the MPL 9000 lithotriptor (five patients). RESULTS: Stone disintegration was achieved in 50 patients (93%), with complete stone clearance in 45 patients (83%) (mean 1.2 session). Patients with successful stone removal after one session had significantly smaller stones than patients with treatment failure (20 +/- 9 versus 27 +/- 8 mm; p < 0.05). An intrahepatic location of stones was significantly associated with treatment failure (p < 0.005). Serve complications occurred in 7% (procedure-related 5%), with a 30-day mortality rate of 0% (in-hospital mortality rate of 2%). Minor side effects such as fever, petechiae, and mild arrhythmias were frequent (37%), and microhematuria (95%) occurred in nearly all of the patients. Symptomatic recurrent bile duct stones were observed in two patients (5%) after three and four years, respectively (mean follow-up 5.3 years). CONCLUSION: Extracorporeal shock wave lithotripsy represents a safe and effective treatment modality for difficult bile duct stones, with a low rate of symptomatic recurrences.